Watch DFTX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
64
WATCH · insiders 28, shorts 99
Insiders, 90 days
−$722K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.1BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$353.8MNET CASH $618.8M52W 9.04 – 48.45SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$75.1M | −$159M | — | -1.44 | −$52.8M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$59.2M | −$77.1M | — | -0.71 | −$42.6M | — | — | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$47.6M | −$50.4M | — | -0.50 | −$43M | — | — | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$45.7M | −$67.3M | — | -0.78 | −$29.6M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$40.9M | −$42.7M | — | -0.50 | −$29.6M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$32.2M | −$23.3M | — | -0.35 | −$29.4M | — | — | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$32.5M | −$34.7M | — | -0.42 | −$25.4M | — | — | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$24.8M | −$13.7M | — | -0.27 | −$17.2M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$24.5M | −$5.9M | — | -0.26 | −$20M | — | — | Jul 31 |
| Q1 2024 · Mar 31 | — | — | — | −$22.2M | −$54.4M | — | -1.14 | −$16.6M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$22.2M | −$23.9M | — | -0.59 | −$20.6M | — | — | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$21.6M | −$17.9M | — | -0.45 | −$16.6M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$166.3M | −$183.8M | — | -2.06 | −$131.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$103.9M | −$108.7M | — | -1.54 | −$79.1M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$93.9M | −$95.7M | — | -2.44 | −$64.4M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$66.3M | −$56.8M | — | -1.84 | −$50.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$93.9M | −$93M | — | -3.40 | −$45.8M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$33M | −$33.9M | — | -0.13 | −$23.6M | — | — | — | — |
Every number comes from Definium Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.